Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal juncti...
Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
About this item
Full title
Author / Creator
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Zolbetuximab is a chimeric monoclonal antibody that targets claudin‐18.2, a candidate biomarker in patients with advanced gastric/gastroesophageal cancer. This nonrandomized phase 1 study (NCT03528629) enrolled previously treated Japanese patients with claudin‐18.2–positive locally advanced/metastatic gastric/gastroesophageal cancer in two parts: S...
Alternative Titles
Full title
Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10067400
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10067400
Other Identifiers
ISSN
1347-9032
E-ISSN
1349-7006
DOI
10.1111/cas.15684
